Reviewed,
UniProtKB/Swiss-Prot O75398 (DEAF1_HUMAN)
Last modified
November 25, 2008.
Version 84.
History...
Clusters with 100%,
90%,
50% identity |
Documents (6) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Deformed epidermal autoregulatory factor 1 homolog Alternative name(s): Nuclear DEAF-1-related transcriptional regulator Short name=NUDR Suppressin Zinc finger MYND domain-containing protein 5 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 565 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is not processed. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Transcription factor that binds to sequence with multiple copies of TTC[CG]G present in its own promoter and that of the HNRPA2B1 gene. Down-regulates transcription of these genes. Binds to the retinoic acid response element (RARE) AGGGTTCACCGAAAGTTCA. Activates the proenkephalin gene independently of promoter binding, probably through protein-protein interaction. When secreted, behaves as an inhibitor of cell proliferation, by arresting cells in the G0 or G1 phase. |
| Subunit structure | Homodimer Probable. Binds to LMO4 (via its C-terminus), LMO2 and CLIM2 By similarity. May interact with the corepressor NCOR. |
| Subcellular location | Nucleus. Note= Cytoplasmic in non-mucinous colorectal carcinoma. Isoform 3: Secreted. Note= Secreted in some cell types. Isoform 4: Secreted. Note= Secreted in some cell types. |
| Tissue specificity | Expressed in various tissues and cells such as in peripheral mononuclear cells and hormone-secreting pituitary cells. |
| Involvement in disease | Defects in DEAF1 could confer a growth advantage to the mutated cell that may have implications for the development and progression of neoplasia, e.g. in the case of colorectal adenocarcinomas (CRC). |
| Miscellaneous | Subcellular location in CRC (cytoplasmic or nuclear) is a prognostic factor that identifies a subgroup of patients with reduced survival. In addition, changes in the subcellular location correlates with the proliferative status of the cells. |
| Sequence similarities | Contains 1 MYND-type zinc finger. Contains 1 SAND domain. |
| Caution | This protein was first known as suppressin (characterized in bovine neuroendocrine and immune cells). However, according to Ref.1, it is uncertain whether it corresponds really to the suppressin also described in Ref.3. DEAF1 has been described as a nuclear dimeric protein and suppressin as a secreted monomeric protein. |
Ontologies
Keywords | |
|---|---|
| Biological process | Transcription Transcription regulation |
| Cellular component | Nucleus Secreted |
| Coding sequence diversity | Alternative splicing |
| Disease | Disease mutation |
| Domain | Zinc-finger |
| Ligand | DNA-binding Metal-binding Zinc |
| PTM | Phosphoprotein |
| Technical term | 3D-structure |
Gene Ontology (GO) | |
| Biological process | anatomical structure morphogenesis Ref.1 Traceable author statement. Source: ProtInc germ cell development Ref.1Traceable author statement. Source: ProtInc regulation of transcription, DNA-dependentInferred from electronic annotation. Source: UniProtKB-KW transcription from RNA polymerase II promoter Ref.1Traceable author statement. Source: ProtInc |
| Cellular component | extracellular region Inferred from electronic annotation. Source: UniProtKB-KW |
| Molecular function | DNA binding Inferred from electronic annotation. Source: InterPro zinc ion bindingInferred from electronic annotation. Source: InterPro |
| Complete GO annotation... | |
Alternative products
| This entry describes 3 isoforms produced by alternative splicing. [Align] [Select] Notes: Experimental confirmation may be lacking for some isoforms. | ||||||
| Isoform 1 (identifier: O75398-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 3 (identifier: O75398-3) Also known as: NUDR8; The sequence of this isoform differs from the canonical sequence as follows: 15-29: EAAAVAAAAAVAAAA → D | ||||||
| Notes: Secreted in some cell types. | ||||||
| Isoform 4 (identifier: O75398-4) Also known as: Suppressin; The sequence of this isoform differs from the canonical sequence as follows: 1-68: Missing. | ||||||
| Notes: Secreted in some cell types. Have no predictable signal peptide. Ref.2 (AAC25718/AAC25719) sequences differ from that shown due to frameshifts in positions 222 and 236. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||||||||||
Molecule processing | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 565 | 565 | Deformed epidermal autoregulatory factor 1 homolog | PRO_0000074084 | |||||||||||||||||
Regions | |||||||||||||||||||||
| Domain | 193 – 273 | 81 | SAND | ||||||||||||||||||
| Zinc finger | 504 – 540 | 37 | MYND-type | ||||||||||||||||||
| Motif | 301 – 316 | 16 | Nuclear localization signal Potential | ||||||||||||||||||
| Compositional bias | 2 – 122 | 121 | Ala-rich | ||||||||||||||||||
| Compositional bias | 383 – 439 | 57 | Pro-rich | ||||||||||||||||||
Amino acid modifications | |||||||||||||||||||||
| Modified residue | 176 | 1 | Phosphoserine | ||||||||||||||||||
Natural variations | |||||||||||||||||||||
| Alternative sequence | 1 – 68 | 68 | Missing in isoform 4. | VSP_005966 | |||||||||||||||||
| Alternative sequence | 15 – 29 | 15 | EAAAV…VAAAA → D in isoform 3. | VSP_005967 | |||||||||||||||||
| Natural variant | 186 | 1 | E → V in a primary colorectal cancer. | VAR_013725 | |||||||||||||||||
| Natural variant | 191 | 1 | K → I in a primary colorectal cancer. | VAR_013726 | |||||||||||||||||
| Natural variant | 191 | 1 | K → N in a primary colorectal cancer. | VAR_013727 | |||||||||||||||||
| Natural variant | 199 – 202 | 4 | YDSE → CDND in a primary colorectal cancer. | VAR_013728 | |||||||||||||||||
| Natural variant | 202 | 1 | E → D in a primary colorectal cancer. | VAR_013729 | |||||||||||||||||
| Natural variant | 218 | 1 | R → K in a primary colorectal cancer. | VAR_013730 | |||||||||||||||||
| Natural variant | 350 – 352 | 3 | DRA → GQT in a primary colorectal cancer. | VAR_013731 | |||||||||||||||||
| Natural variant | 356 | 1 | E → H in a primary colorectal cancer; requires 2 nucleotide substitutions. | VAR_013732 | |||||||||||||||||
| Natural variant | 364 | 1 | S → N in a primary colorectal cancer. | VAR_013733 | |||||||||||||||||
| Natural variant | 367 | 1 | Q → H in a primary colorectal cancer. | VAR_013734 | |||||||||||||||||
| Natural variant | 370 | 1 | V → L in a primary colorectal cancer. | VAR_013735 | |||||||||||||||||
| Natural variant | 397 | 1 | Y → F in a primary colorectal cancer. | VAR_013736 | |||||||||||||||||
| Natural variant | 442 | 1 | V → A in a primary colorectal cancer. | VAR_013737 | |||||||||||||||||
| Natural variant | 449 | 1 | E → K in a primary colorectal cancer. | VAR_013738 | |||||||||||||||||
| Natural variant | 451 – 452 | 2 | RS → GI in a primary colorectal cancer. | VAR_013739 | |||||||||||||||||
| Natural variant | 468 | 1 | Q → H in a primary colorectal cancer. | VAR_013740 | |||||||||||||||||
| Natural variant | 479 | 1 | H → L in a primary colorectal cancer. | VAR_013741 | |||||||||||||||||
| Natural variant | 498 | 1 | E → K in a primary colorectal cancer. | VAR_013742 | |||||||||||||||||
| Natural variant | 526 | 1 | T → N in a primary colorectal cancer. | VAR_013743 | |||||||||||||||||
| Natural variant | 530 | 1 | R → L in a primary colorectal cancer. | VAR_013744 | |||||||||||||||||
| Natural variant | 537 – 538 | 2 | QH → HL in a primary colorectal cancer. | VAR_013745 | |||||||||||||||||
| Natural variant | 542 | 1 | Q → H in a primary colorectal cancer. | VAR_013746 | |||||||||||||||||
| Natural variant | 545 | 1 | A → G in a primary colorectal cancer. | VAR_013747 | |||||||||||||||||
| Natural variant | 545 | 1 | A → V in a primary colorectal cancer. | VAR_013748 | |||||||||||||||||
Experimental info | |||||||||||||||||||||
| Mutagenesis | 215 | 1 | Y → Q: Reduces transcription activation | ||||||||||||||||||
| Mutagenesis | 226 | 1 | R → A: Reduces transcription activation | ||||||||||||||||||
| Mutagenesis | 246 | 1 | R → A: Reduces transcription activation | ||||||||||||||||||
| Mutagenesis | 250 | 1 | K → A: Abolishes DNA-binding | ||||||||||||||||||
| Mutagenesis | 252 | 1 | W → Q: Abolishes DNA-binding | ||||||||||||||||||
| Mutagenesis | 253 | 1 | K → A: Abolishes DNA-binding | ||||||||||||||||||
| Mutagenesis | 302 | 1 | R → T: Abolishes nuclear localization | ||||||||||||||||||
| Mutagenesis | 304 | 1 | K → T: Abolishes nuclear localization | ||||||||||||||||||
| Sequence conflict | 72 | 1 | E → D in AAB62704. Ref.3 | ||||||||||||||||||
| Sequence conflict | 247 | 1 | A → T in AAB62704. Ref.3 | ||||||||||||||||||
| Sequence conflict | 294 | 1 | V → L in AAB62704. Ref.3 | ||||||||||||||||||
| Sequence conflict | 380 | 1 | S → I in AAC25718. Ref.2 | ||||||||||||||||||
| Sequence conflict | 440 | 1 | A → E in AAC25718. Ref.2 | ||||||||||||||||||
| Sequence conflict | 457 | 1 | E → K in AAC25718. Ref.2 | ||||||||||||||||||
| Sequence conflict | 482 | 1 | T → S in AAC25718. Ref.2 | ||||||||||||||||||
| Sequence conflict | 487 | 1 | A → G in AAC25718. Ref.2 | ||||||||||||||||||
| Sequence conflict | 496 – 497 | 2 | DA → VS in AAC25718. Ref.2 | ||||||||||||||||||
| Sequence conflict | 502 | 1 | Q → H in AAC25718. Ref.2 | ||||||||||||||||||
| Sequence conflict | 522 | 1 | N → K in AAB62704. Ref.3 | ||||||||||||||||||
Secondary structure | |||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||
| Beta strand | 505 – 510 | 6 | |||||||||||||||||||
| Beta strand | 512 – 514 | 3 | |||||||||||||||||||
| Turn | 516 – 518 | 3 | |||||||||||||||||||
| Beta strand | 520 – 525 | 6 | |||||||||||||||||||
| Helix | 526 – 532 | 7 | |||||||||||||||||||
| Turn | 533 – 535 | 3 | |||||||||||||||||||
| Helix | 536 – 538 | 3 | |||||||||||||||||||
| Turn | 539 – 541 | 3 | |||||||||||||||||||
Sequences
| ||||||||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Characterization of a nuclear deformed epidermal autoregulatory factor-1 (DEAF-1)-related (NUDR) transcriptional regulator protein." Huggenvik J.I., Michelson R.J., Collard M.W., Ziemba A.J., Gurley P., Mowen K.A. Mol. Endocrinol. 12:1619-1639(1998) [PubMed: 9773984] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), MUTAGENESIS OF ARG-302 AND LYS-304. Tissue: Choriocarcinoma. |
| [2] | "Altered subcellular localization of suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas." Manne U., Gary B.D., Oelschlager D.K., Weiss H.L., Frost A.R., Grizzle W.E. Clin. Cancer Res. 7:3495-3503(2001) [PubMed: 11705868] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), VARIANTS CRC VAL-186; ASN-191; ILE-191; 199-CYS-ASP-ASN-ASP-202; ASP-202; LYS-218; 350-GLY-GLN-THR-352; HIS-356; ASN-364; HIS-367; LEU-370; PHE-397; ALA-442; LYS-449; 451-GLY-ILE-452; HIS-468; LEU-479; LYS-498; ASN-526; LEU-530; 537-HIS-LEU-538; HIS-542; GLY-545 AND VAL-545. Tissue: Colon and Colon adenocarcinoma. |
| [3] | "Cloning and sequence analysis of the cDNA for human suppressin (spn)." LeBoeuf R.D., Blalock J.E., Tauber J.D. Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). Tissue: Mammary gland. |
| [4] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). Tissue: Ovary. |
| [5] | "Nuclear DEAF-1-related (NUDR) protein contains a novel DNA binding domain and represses transcription of the heterogeneous nuclear ribonucleoprotein A2/B1 promoter." Michelson R.J., Collard M.W., Ziemba A.J., Persinger J., Bartholomew B., Huggenvik J.I. J. Biol. Chem. 274:30510-30519(1999) [PubMed: 10521432] [Abstract] Cited for: FUNCTION. |
| [6] | "The SAND domain structure defines a novel DNA-binding fold in transcriptional regulation." Bottomley M.J., Collard M.W., Huggenvik J.I., Liu Z., Gibson T.J., Sattler M. Nat. Struct. Biol. 8:626-633(2001) [PubMed: 11427895] [Abstract] Cited for: FUNCTION OF SAND DOMAIN, MUTAGENESIS OF TYR-215; ARG-226; ARG-246; LYS-250; TRP-252 AND LYS-253. |
| [7] | "Large-scale characterization of HeLa cell nuclear phosphoproteins." Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J., Li J., Cohn M.A., Cantley L.C., Gygi S.P. Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004) [PubMed: 15302935] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-176, MASS SPECTROMETRY. Tissue: Epithelium. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |
|---|---|
| AF049459 mRNA. Translation: AAC79676.1. AF049460 mRNA. Translation: AAC79677.1. AF068893 mRNA. Translation: AAC25715.1. AF068894 mRNA. Translation: AAC25716.1. AF068895 mRNA. Translation: AAC25717.1. AF068896 mRNA. Translation: AAC25718.1. Frameshift. AF068897 mRNA. Translation: AAC25719.1. Frameshift. AF007165 mRNA. Translation: AAB62704.1. BC053322 mRNA. Translation: AAH53322.1. | |
| RefSeq | NP_066288.2. |
| UniGene | Hs.243994 Hs.448664 |
3D structure databases | |

Clusters with